- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging mechanisms of enzalutamide resistance in prostate cancer
Authors
Keywords
-
Journal
Nature Reviews Urology
Volume 11, Issue 12, Pages 712-716
Publisher
Springer Nature
Online
2014-09-16
DOI
10.1038/nrurol.2014.243
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- AR Variant ARv567es Induces Carcinogenesis in a Novel Transgenic Mouse Model of Prostate Cancer
- (2015) Gang Liu et al. NEOPLASIA
- Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer
- (2014) Z. Yu et al. CLINICAL CANCER RESEARCH
- Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer
- (2014) Kathryn E Ware et al. ENDOCRINE-RELATED CANCER
- Steroid Receptors Aplenty in Prostate Cancer
- (2014) Nima Sharifi NEW ENGLAND JOURNAL OF MEDICINE
- Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate Cancer
- (2014) Masis Isikbay et al. Hormones & Cancer
- Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
- (2013) K. L. Noonan et al. ANNALS OF ONCOLOGY
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
- (2013) Vivek K. Arora et al. CELL
- Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer
- (2013) R.J. van Soest et al. EUROPEAN JOURNAL OF CANCER
- Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
- (2013) Andres Jan Schrader et al. EUROPEAN UROLOGY
- An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
- (2013) M. Korpal et al. Cancer Discovery
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- Overcoming mutation-based resistance to antiandrogens with rational drug design
- (2013) Minna D Balbas et al. eLife
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- FoxA1 Specifies Unique Androgen and Glucocorticoid Receptor Binding Events in Prostate Cancer Cells
- (2012) B. Sahu et al. CANCER RESEARCH
- Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
- (2012) Y. Li et al. CANCER RESEARCH
- Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells
- (2012) Alexander Yemelyanov et al. CELL CYCLE
- Evidence for DNA-Binding Domain-Ligand-Binding Domain Communications in the Androgen Receptor
- (2012) C. Helsen et al. MOLECULAR AND CELLULAR BIOLOGY
- Androgen receptor (AR) aberrations in castration-resistant prostate cancer
- (2012) Kati K. Waltering et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Adaptation or selection—mechanisms of castration-resistant prostate cancer
- (2012) Yang Zong et al. Nature Reviews Urology
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- A 629RKLKK633 motif in the hinge region controls the androgen receptor at multiple levels
- (2010) Tamzin M. Tanner et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
- (2010) Shihua Sun et al. JOURNAL OF CLINICAL INVESTIGATION
- The Rules of DNA Recognition by the Androgen Receptor
- (2010) Sarah Denayer et al. MOLECULAR ENDOCRINOLOGY
- Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor
- (2010) P. A. Watson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth
- (2009) Z. Guo et al. CANCER RESEARCH
- Antiandrogen withdrawal in castrate-refractory prostate cancer
- (2008) A. Oliver Sartor et al. CANCER
- Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer
- (2008) R. Hu et al. CANCER RESEARCH
- Relationship between Glucocorticoid Receptor Signal Pathway and Androgen-Independent Prostate Cancer
- (2008) Tian-Zhong Yan et al. UROLOGIA INTERNATIONALIS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started